

Introduction

The proceedings of Special Symposium D on Dopamine Receptors and their Behavioral Correlates held in Jerusalem, Israel, on June 22, 1982 in association with the Collegium Internationale Neuro-Psychopharmacologicum 13th C.I.N.P. Congress are presented in this supplement to *Pharmacology, Biochemistry and Behavior*.

Samuel Gershon, M.D., Professor and Chairman, Department of Psychiatry, Wayne State University, Detroit, Michigan, was the Chairman for the Symposium. The clinical implications of dopamine agonists and antagonists in the treatment of anxiety have become more significant and suggest that dopamine is implicated in the etiology of such behavior. The fact that buspirone has an anxiolytic action that does not involve the benzodiazepine-GABA system and also lacks sedative, anticonvulsant, and muscle relaxant properties is very promising both in terms of clinical applications and as a research tool in the study of pathological behavioral states. The symposium was made possible through an educational grant from the Pharmaceutical Division of Mead Johnson & Company, Evansville, Indiana, USA.

MATTHEW J. WAYNER
Editor-in-Chief